Clinigen Group
Market Cap
UK£1.0b
Last Updated
2021/02/23 19:27 UTC
Data Sources
Company Financials +
Executive Summary
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with proven track record.
Similar Companies
Share Price & News
How has Clinigen Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLIN is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CLIN's weekly volatility has decreased from 10% to 4% over the past year.
Market Performance
7 Day Return
-5.5%
CLIN
-1.8%
GB Life Sciences
-1.8%
GB Market
1 Year Return
-2.4%
CLIN
32.4%
GB Life Sciences
-2.0%
GB Market
Return vs Industry: CLIN underperformed the UK Life Sciences industry which returned 26.6% over the past year.
Return vs Market: CLIN exceeded the UK Market which returned -4% over the past year.
Shareholder returns
| CLIN | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.5% | -1.8% | -1.8% |
| 30 Day | 0.6% | 4.6% | -0.1% |
| 90 Day | 12.9% | 26.4% | 5.9% |
| 1 Year | -1.0%-2.4% | 33.1%32.4% | 2.1%-2.0% |
| 3 Year | -23.6%-25.7% | 29.4%27.4% | 8.5%-4.5% |
| 5 Year | 17.9%13.4% | 75.5%71.9% | 41.2%14.0% |
Long-Term Price Volatility Vs. Market
How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
A Look At Clinigen Group's (LON:CLIN) Share Price Returns3 weeks ago | Simply Wall St
Clinigen Group plc's (LON:CLIN) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?1 month ago | Simply Wall St
When Should You Buy Clinigen Group plc (LON:CLIN)?Valuation
Is Clinigen Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CLIN (£7.2) is trading below our estimate of fair value (£16.45)
Significantly Below Fair Value: CLIN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CLIN is poor value based on its PE Ratio (69.7x) compared to the GB Life Sciences industry average (44x).
PE vs Market: CLIN is poor value based on its PE Ratio (69.7x) compared to the UK market (23.5x).
Price to Earnings Growth Ratio
PEG Ratio: CLIN is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: CLIN is good value based on its PB Ratio (2.1x) compared to the GB Life Sciences industry average (4.7x).
Next Steps
Future Growth
How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
38.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLIN's forecast earnings growth (38.1% per year) is above the savings rate (1%).
Earnings vs Market: CLIN's earnings (38.1% per year) are forecast to grow faster than the UK market (23.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLIN's revenue (12.9% per year) is forecast to grow faster than the UK market (7% per year).
High Growth Revenue: CLIN's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLIN's Return on Equity is forecast to be high in 3 years time (20.7%)
Next Steps
Past Performance
How has Clinigen Group performed over the past 5 years?
17.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLIN has a large one-off loss of £38.2M impacting its June 30 2020 financial results.
Growing Profit Margin: CLIN's current net profit margins (2.7%) are higher than last year (1.1%).
Past Earnings Growth Analysis
Earnings Trend: CLIN's earnings have grown by 17.7% per year over the past 5 years.
Accelerating Growth: CLIN's earnings growth over the past year (161%) exceeds its 5-year average (17.7% per year).
Earnings vs Industry: CLIN earnings growth over the past year (161%) exceeded the Life Sciences industry 31.5%.
Return on Equity
High ROE: CLIN's Return on Equity (3.1%) is considered low.
Next Steps
Financial Health
How is Clinigen Group's financial position?
Financial Position Analysis
Short Term Liabilities: CLIN's short term assets (£312.7M) exceed its short term liabilities (£203.2M).
Long Term Liabilities: CLIN's short term assets (£312.7M) do not cover its long term liabilities (£493.2M).
Debt to Equity History and Analysis
Debt Level: CLIN's debt to equity ratio (95.9%) is considered high.
Reducing Debt: CLIN's debt to equity ratio has increased from 50.8% to 95.9% over the past 5 years.
Debt Coverage: CLIN's debt is not well covered by operating cash flow (14.2%).
Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (6.5x coverage).
Balance Sheet
Next Steps
Dividend
What is Clinigen Group current dividend yield, its reliability and sustainability?
1.06%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLIN's dividend (1.06%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.49%).
High Dividend: CLIN's dividend (1.06%) is low compared to the top 25% of dividend payers in the UK market (4.55%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CLIN has been paying a dividend for less than 10 years.
Growing Dividend: CLIN's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (73.7%), CLIN's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CLIN's dividends in 3 years are forecast to be thoroughly covered by earnings (11.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Shaun Chilton (52 yo)
4.25yrs
Tenure
UK£1,489,000
Compensation
Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016 & has the responsibility for the Group achieving its KPIs and plays a central role in setting the...
CEO Compensation Analysis
Compensation vs Market: Shaun's total compensation ($USD2.10M) is about average for companies of similar size in the UK market ($USD1.71M).
Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.25yrs | UK£1.49m | 0.25% £ 2.5m | |
| CFO & Executive Director | 1.92yrs | UK£556.00k | 0.0076% £ 76.4k | |
| Chief Operating Officer | 0.083yr | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Company Secretary | 3.67yrs | no data | no data | |
| Director of Corporate Development | 6.58yrs | no data | no data | |
| Global Human Resources Director | 4.25yrs | no data | no data | |
| Managing Director of Global Access Division | 7.58yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Chief Medial Officer | 5yrs | no data | no data | |
| Senior Vice President of Clinical Trial Services | 2.92yrs | no data | no data | |
| Senior Vice President of Unlicensed Medicines | 2.42yrs | no data | no data |
4.3yrs
Average Tenure
52yo
Average Age
Experienced Management: CLIN's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.25yrs | UK£1.49m | 0.25% £ 2.5m | |
| CFO & Executive Director | 1.92yrs | UK£556.00k | 0.0076% £ 76.4k | |
| Chief Commercial Officer | no data | no data | no data | |
| Independent Non-Executive Director | 8.42yrs | UK£70.00k | 0.0098% £ 98.4k | |
| Independent Non-Executive Chairman | 8.5yrs | UK£143.00k | 0.039% £ 395.4k | |
| Non-Executive Director | 2.25yrs | UK£60.00k | 0.0053% £ 53.0k | |
| Senior Independent Director | 0.25yr | UK£70.00k | 0.0089% £ 89.7k |
4.9yrs
Average Tenure
59.5yo
Average Age
Experienced Board: CLIN's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Clinigen Group plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Clinigen Group plc
- Ticker: CLIN
- Exchange: AIM
- Founded: 2008
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£1.007b
- Shares outstanding: 133.02m
- Website: https://www.clinigengroup.com
Number of Employees
Location
- Clinigen Group plc
- Pitcairn House
- Crown Square
- Burton-on-Trent
- Staffordshire
- DE14 2WW
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CLIN | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Sep 2012 |
| CLIG.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Sep 2012 |
| 78C | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Sep 2012 |
| CGNG.Y | OTCPK (Pink Sheets LLC) | UNSPONSORE ADR | US | USD | Mar 2017 |
Biography
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segmen...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/23 19:27 |
| End of Day Share Price | 2021/02/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.